Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapseCraig H. Moskowitz, John Sweetenham, Muneer H. Abidi et al.|Blood|2018Cited by 250
Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplantLyle Feinstein, Rainer Storb, Brenda M. Sandmaier et al.|Transplantation and Cellular Therapy|2003Cited by 33
Allogeneic Hematopoietic Cell Transplantation (HCT) with Nonmyeloablative Conditioning after Failed Myeloablative HCT: Factors Affecting Outcomes.Frédéric Baron, Brenda M. Sandmaier, Rainer Storb et al.|Blood|2005Cited by 1